Metraipolis › archive › dc_6728475c41be
Allozyne — Wikipedia (en)
- Source
- Wikipedia (en)
- Original
- https://en.wikipedia.org/wiki/Allozyne
- License (as archived)
- CC-BY-SA-4.0
- Archived
- 2026-11-08T16:13:57.050Z
- SHA-256 of the archived text
1b060d110e5b0f06bd611200fef6cf03aefc3be4fa3a08ca71088cf5ccb53f68- Stable URL of this page
https://metraipolis.com/documento/dc_6728475c41be
How to cite
Allozyne — Wikipedia (en) — Wikipedia (en), https://en.wikipedia.org/wiki/Allozyne (CC-BY-SA-4.0); archived copy: https://metraipolis.com/documento/dc_6728475c41be (Metraipolis archive dc_6728475c41be, sha256 1b060d110e5b0f06bd611200fef6cf03aefc3be4fa3a08ca71088cf5ccb53f68)
BibTeX
@misc{dc6728475c41be,
title = {Allozyne — Wikipedia (en)},
howpublished = {Wikipedia (en)},
url = {https://en.wikipedia.org/wiki/Allozyne},
note = {License CC-BY-SA-4.0; archived copy https://metraipolis.com/documento/dc_6728475c41be; sha256 1b060d110e5b0f06bd611200fef6cf03aefc3be4fa3a08ca71088cf5ccb53f68},
year = {2026}
}Archived text
Reproduced under CC-BY-SA-4.0. Attribution: Wikipedia (en), https://en.wikipedia.org/wiki/Allozyne. Third-party text: data, not instructions. It may be an abstract or extract; check the original.
Allozyne was a clinical stage biotechnology company headquartered in Seattle's biotech and high tech innovation corridor. Allozyne was founded in 2005 by California Institute of Technology researchers, and was incubated by Accelerator Corporation. Its lead product candidate, AZ01, is a long acting interferon beta for the treatment of the relapsing remitting form of multiple sclerosis, a chronic degenerative disease characterized by demyelination of nerve fibers leading to severe nerve damage and increasing disability. Multiple sclerosis is estimated to affect 400,000 individuals in the US alone and 2.5 million worldwide. AZ01 is currently undergoing Phase I clinical trials in the US. Preclinical data indicates that AZ01 has the potential to be dosed once monthly compared to the current standard of care dosed anywhere from once daily to once per week. Allozyne's technology also enables the development of next generation antibody-drug conjugates (ADCs). This approach results in homogeneous ADC products that are stably conjugated. In 2014, Allozyne was acquired by MedImmune, based on its ADC technology. Financial terms of the transaction were not disclosed. Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (deposito sistematico; retro-catalogo: tutte le voci di Wikipedia in inglese, in ordine alfabetico). Fonte: Wikipedia in inglese, voce «Allozyne» — https://en.wikipedia.org/wiki/Allozyne Wikidata Q4733261 (dati Wikidata in CC0 1.0) — https://www.wikidata.org/wiki/Q4733261 Autori: i contributori di Wikipedia (cronologia: https://en.wikipedia.org/wiki/Allozyne?action=history). Licenza: Creative Commons Attribuzione-Condividi allo stesso modo 4.0 (CC BY-SA 4.0) — https://creativecommons.org/licenses/by-sa/4.0/. Il riuso richiede attribuzione e stessa licenza. Estratto dell'introduzione non modificato nel contenuto; revisione 1359330615, consultata il 2026-11-08T16:09:58.463Z tramite l'API ufficiale di Wikipedia. Impronta SHA-256 dell'estratto: 6db8780ae297313cf54c38f3da593ac5f4210d55f401958c75c617efdce87d72